CSPM EDP Sciences logo
Access to submission and peer review system
Search
Menu
All issues Volume 7 (2026) Vis Cancer Med, 7 (2026) 3 References
Open Access
Review
Issue
Vis Cancer Med
Volume 7, 2026
Article Number 3
Number of page(s) 12
DOI https://doi.org/10.1051/vcm/2026002
Published online 09 June 2026
  1. Nussbaum YI, Manjunath Y, Suvilesh KN, et al. Current and prospective methods for assessing anti-tumor immunity in colorectal cancer. Int J Mol Sci. 2021;22:4802. https://doi.org/10.3390/ijms22094802. [Google Scholar]
  2. Shivshankar S, Patil PS, Deodhar K, et al. Epidemiology of colorectal cancer: A review with special emphasis on India. Indian J Gastroenterol. 2025;44:142–153. https://doi.org/10.1007/s12664-024-01726-8. [Google Scholar]
  3. CRI New York, 2025 – https://www.cancerresearch.org/blog/colorectal-cancer-awareness-month#_ftn1. [Google Scholar]
  4. Hamzehzadeh L, Imanparast A, Tajbakhsh A, et al. New approaches to use nanoparticles for treatment of colorectal cancer; a brief review. Nanomed Res J. Tehran University of Medical Sciences 2016a;1:59–68. https://doi.org/10.7508/NMRJ.2016.02.001. [Google Scholar]
  5. WHO, 2023 – https://www.who.int/news-room/fact-sheets/detail/colorectal-cancer. [Google Scholar]
  6. Banerjee A, Pathak S, Subramanium VD, et al. Strategies for targeted drug delivery in treatment of colon cancer: current trends and future perspectives. Drug Discovery Today. 2017;22:1224–1232. https://doi.org/10.1016/j.drudis.2017.05.006. [Google Scholar]
  7. Patel K, Jain P, Rajput PK, et al. Human serum albumin-based propulsive Piperlongumine-loaded nanoparticles: Formulation development, characterization and anti-cancer study. Colloids Surf A: Physicochem Eng Aspects. 2022;652:129738. https://doi.org/10.1016/j.colsurfa.2022.129738. [Google Scholar]
  8. Reddy RG, Suvarna DVAH, Kumar RVT. Colorectal cancer in India: An audit from a tertiary care centre. Res Article J MAR Gastroenterol. 2023;2:1. www.medicalandresearch.com. https://www.medicalandresearch.com/previous_view/1146. [Google Scholar]
  9. Ghazarian H, Idoni B, Oppenheimer SB. A glycobiology review: Carbohydrates, lectins and implications in cancer therapeutics. Acta Histochemica. 2011;113:236–247. https://doi.org/10.1016/j.acthis.2010.02.004. [Google Scholar]
  10. Castro E, Kumar A. Nanoparticles in drug delivery systems. In Nanomedicine in drug delivery . CRC Press;2013. p. 1–22. https://doi.org/10.1201/b14802. [Google Scholar]
  11. Davis ME, Chen Z, Shin DM. Nanoparticle therapeutics: An emerging treatment modality for cancer. In Nature reviews drug discovery (Vol. 7). Nature Publishing Group; 2008. p. 771–782. https://doi.org/10.1038/nrd2614. [Google Scholar]
  12. Cepero A, Luque C, Cabeza L, et al. Antibody-functionalized nanoformulations for targeted therapy of colorectal cancer: A systematic review. Int J Nanomed. 2022;17:5065–5080. Dove Medical Press Ltd. https://doi.org/10.2147/IJN.S368814. [Google Scholar]
  13. Wang AZ, Langer R, Farokhzad OC. Nanoparticle delivery of cancer drugs. Annu Rev Med. 2012;63:185–198. https://doi.org/10.1146/annurev-med-040210-162544. [Google Scholar]
  14. Menon DS, Abira R, Gokarn S, et al. Multifaceted peptide-based nanoparticles for diagnosis of brain tumors: Recent advances and future outlooks. J Biotech Biomed. 2025;8:59–71. https://doi.org/10.26502/jbb.2642-91280179. [Google Scholar]
  15. Amaral M, Hamad H, Menon DS, et al. The effect of cynaropicrin, a sesquiterpene lactone, on the migratory properties of triple-negative breast cancer cells and the underlying mechanisms. Avicenna J Phytomed. 2025;16:66–77. https://doi.org/10.22038/ajp.2025.25894. [Google Scholar]
  16. Al-Joufi FA, Setia A, Salem-Bekhit MM, et al. Molecular pathogenesis of colorectal cancer with an emphasis on recent advances in biomarkers, as well as nanotechnology-based diagnostic and therapeutic approaches. Nanomaterials. 2022;12(1):169. https://doi.org/10.3390/nano12010169. [Google Scholar]
  17. Narayana S, Gowda BHJ, Hani U, et al. Inorganic nanoparticle-based treatment approaches for colorectal cancer: recent advancements and challenges. J Nanobiotechnol. 2024;22:427. https://doi.org/10.1186/s12951-024-02701-3. [Google Scholar]
  18. Robles AI, Traverso G, Zhang M, et al. Whole-exome sequencing analyses of inflammatory bowel disease-associated colorectal cancers. Gastroenterology. 2016;150:931–943. https://doi.org/10.1053/j.gastro.2015.12.036. [Google Scholar]
  19. Swiderska M, Choromańska B, Dąbrowska E, et al. The diagnostics of colorectal cancer. Contemp Oncol (Poznan, Poland). 2014;18:1–6. https://doi.org/10.5114/wo.2013.39995. [Google Scholar]
  20. Levin B, Lieberman DA, McFarland B, et al. Screening and surveillance for the early detection of colorectal cancer and adenomatous polyps, 2008: A joint guideline from the american cancer society, the US multi-society task force on colorectal cancer, and the American college of radiology. CA: A Cancer J Clin. 2008;58:130–160. https://doi.org/10.3322/ca.2007.0018. [Google Scholar]
  21. Szajda SD, Borzym-Kluczyk M, Snarska J, et al. N-acetyl-β-D-hexosaminidase and its isoenzymes A and B in blood serum and urine, as a potential colon cancer markers. Hepato-Gastroenterol. 2009;56:1287–1298. [Google Scholar]
  22. Zhang YL, Zhang ZS, Wu BP, et al. Early diagnosis for colorectal cancer in China. World J Gastroenterol. 2002;8(1):21–25. https://doi.org/10.3748/wjg.v8.i1.21. [Google Scholar]
  23. Tang X, Liang Y, Feng X, et al. Co-delivery of docetaxel and Poloxamer 235 by PLGA-TPGS nanoparticles for breast cancer treatment. Mater Sci Eng C. 2015;49:348–355. https://doi.org/10.1016/j.msec.2015.01.033. [Google Scholar]
  24. Ades S. Adjuvant chemotherapy for colon cancer in the elderly: Moving from evidence to practice. Oncology. 2009;23:162–167. [Google Scholar]
  25. Kumar A, Gautam V, Sandhu A, et al. Current and emerging therapeutic approaches for colorectal cancer: A comprehensive review. World J Gastrointest Surg. 2023; 15(4):495–519. https://doi.org/10.4240/wjgs.v15.i4.495. [Google Scholar]
  26. Zhang YR, Zhu HR, Li HR, et al. Trends in nanomedicine for colorectal cancer treatment: Bibliometric and visualization analysis (2010–2024). World Journal of Gastrointest Oncol. 2025;17(4):102438. https://doi.org/10.4251/wjgo.v17.i4.102438. [Google Scholar]
  27. Overman MJ, Lonardi S, Wong KYM, et al. Durable clinical benefit with nivolumab plus ipilimumab in DNA mismatch repair-deficient/microsatellite instability-high metastatic colorectal cancer. J Clin Oncol. 2018;36:773–779. https://doi.org/10.1200/JCO.2017.76.9901. [Google Scholar]
  28. Viralippurath Ashraf J, Sasidharan Nair V, Saleh R, et al. Role of circular RNAs in colorectal tumor microenvironment. In Biomedicine and pharmacotherapy (Vol. 137). Elsevier Masson s.r.l; 2021. https://doi.org/10.1016/j.biopha.2021.111351. [Google Scholar]
  29. Raju GSR, Pavitra E, Varaprasad GL, et al. Nanoparticles mediated tumor microenvironment modulation: current advances and applications. J Nanobiotechnol. 2022;20:274. https://doi.org/10.1186/s12951-022-01476-9. [Google Scholar]
  30. Yang M, Li J, Gu P, et al. The application of nanoparticles in cancer immunotherapy: Targeting tumor microenvironment. Bioact Mater. 2021;6(7):1973–1987. https://doi.org/1s0.1016/j.bioactmat.2020.12.010. [Google Scholar]
  31. Pandit S, Dutta D, Nie S. Active transcytosis and new opportunities for cancer nanomedicine. Nat Mater. 2020;19(5):478–480. https://doi.org/10.1038/s41563-020-0672-1. [Google Scholar]
  32. Maeda H. Toward a full understanding of the EPR effect in primary and metastatic tumors as well as issues related to its heterogeneity. Adv Drug Delivery Rev. 2015;91:3–6. https://doi.org/10.1016/j.addr.2015.01.002. [Google Scholar]
  33. Li X, Hu Y, Zhang X, et al. Transvascular transport of nanocarriers for tumor delivery. Nat Commun. 2024;15:8172. https://doi.org/10.1038/s41467-024-52416-0. [Google Scholar]
  34. Hasan M, Evett C, Burton J. Advances in nanoparticle-based targeted drug delivery systems for colorectal cancer therapy: A review. arXiv. 2024. https://doi.org/10.48550/arXiv.2409.05222. [Google Scholar]
  35. Rodrigues P, Thiab A, Jabir M, et al. Combination therapies and novel delivery systems: A new frontier in overcoming TRAIL resistance in gastric cancer. Naunyn-Schmiedeberg's Archives of Pharmacology. 2025;398:13581–13603. https://doi.org/10.1007/s00210-025-04208-6. [Google Scholar]
  36. Carvalho MR, Carvalho CR, Maia FR, et al. Peptide-modified dendrimer nanoparticles for targeted therapy of colorectal cancer. Adv Ther. 2019;2:1900132. https://doi.org/10.1002/adtp.201900132. [Google Scholar]
  37. Briolay T, Petithomme T, Fouet M, et al. Delivery of cancer therapies by synthetic and bio-inspired nanovectors. In Molecular cancer (Vol. 20). BioMed Central Ltd; 2021. https://doi.org/10.1186/s12943-021-01346-2. [Google Scholar]
  38. Choi KY, Jeon EJ, Yoon HY, et al. Theranostic nanoparticles based on PEGylated hyaluronic acid for the diagnosis, therapy and monitoring of colon cancer. Biomaterials. 2012;33(26):6186–6193. https://doi.org/10.1016/j.biomaterials.2012.05.029. [Google Scholar]
  39. Alkhader E, Roberts CJ, Rosli R, et al. Pharmacokinetic and anti-colon cancer properties of curcumin-containing chitosan-pectinate composite nanoparticles. J Biomater Sci Polymer Ed. 2018;29(18):2281–2298. https://doi.org/10.1080/09205063.2018.1541500. [Google Scholar]
  40. Baylisss CE, Houston AP. Characterization of plant polysaccharide- and mucin-fermenting anaerobic bacteria from human feces. Appl Environ Microbiol. 1984;48:626–632. https://doi.org/10.1128/aem.48.3.626-632.1984. [Google Scholar]
  41. Lee PC, Chiou YC, Wong JM, et al. Targeting colorectal cancer cells with single-walled carbon nanotubes conjugated to anticancer agent SN-38 and EGFR antibody. Biomaterials. 2013;34:8756–8765. https://doi.org/10.1016/j.biomaterials.2013.07.067. [Google Scholar]
  42. Venturini J, Chakraborty A, Baysal MA et al. Developments in nanotechnology approaches for the treatment of solid tumors. Exp Hematol Oncol. 2025;14:76. https://doi.org/10.1186/s40164-025-00656-1. [Google Scholar]
  43. Batist G, Sawyer M, Gabrail N, et al. A multicenter, phase II study of CPX-1 liposome injection in patients (pts) with advanced colorectal cancer (CRC). J Clin Oncol. 2008;26:4108–4108. https://doi.org/10.1200/jco.2008.26.15_suppl.4108. [Google Scholar]
  44. Gogoi P, Kaur G, Singh NK. Nanotechnology for colorectal cancer detection and treatment. World J Gastroenterol. 2022;28:6497–6511. Baishideng Publishing Group Inc. https://doi.org/10.3748/wjg.v28.i46.6497. [Google Scholar]
  45. Dou Y, Hynynen K, Allen C. To heat or not to heat: Challenges with clinical translation of thermosensitive liposomes. J Controlled Release. 2017;249: 63–73. https://doi.org/10.1016/j.jconrel.2017.01.025. [Google Scholar]
  46. Yin L, Li H, Shi L, et al. Research advances in nanomedicine applied to the systemic treatment of colorectal cancer. Int J Cancer. 2023;152:807–821. [Google Scholar]
  47. Ter Haar G; Shaw A. Requirements for measurement standards in high intensity ultrasound (HIFU) fields. NPL Rep. 2006;15:DQL-AC 015. [Google Scholar]
  48. Arulpragasam AR, van ’t Wout-Frank M, Barredo J, et al. Low intensity focused ultrasound for non-invasive and reversible deep brain neuromodulation – a paradigm shift in psychiatric research. Front Psychiatry. 2022;13:825802. [Google Scholar]
  49. Farooqi MA, Mahnoor M, Delgado KM, et al. Focused ultrasound as targeted therapy for colorectal cancer: A comprehensive review. Gastrointest Disord. 2024;6(2):380–401. https://doi.org/10.3390/gidisord6020026. [Google Scholar]
  50. Barenholz Y. Doxil® - The first FDA-approved nano-drug: Lessons learned J Controlled Release. 2012;160:117–134. https://doi.org/10.1016/j.jconrel.2012.03.020. [Google Scholar]
  51. Campos S. Liposomal anthracyclines: Adjuvant and neoadjuvant therapy for breast cancer. Oncologist. 2003;8:10–16. https://doi.org/10.1634/theoncologist.8-suppl_2-10. [Google Scholar]
  52. Udaipuria N, Bhattacharya S. Novel carbohydrate polymer-based systems for precise drug delivery in colon cancer: improving treatment effectiveness with intelligent biodegradable materials. Biopolymers. 2024;116(1):e23632. https://doi.org/10.1002/bip.23632. [Google Scholar]
  53. Sun Y, Li B, Cao Q, et al. Targeting cancer stem cells with polymer nanoparticles for gastrointestinal cancer treatment. Stem Cell Res Ther. 2022;13:489. https://doi.org/10.1186/s13287-022-03180-9. [Google Scholar]
  54. Subudhi MB, Jain A, Jain A, et al. Eudragit S100 coated citrus pectin nanoparticles for colon targeting of 5-fluorouracil. Mater (Basel, Switzerland). 2015;8(3):832–849. https://doi.org/10.3390/ma8030832. [Google Scholar]
  55. Tummala S, Satish Kumar MN, Prakash A. Formulation and characterization of 5-Fluorouracil enteric coated nanoparticles for sustained and localized release in treating colorectal cancer. Saudi Pharm J. 2015;23:308–314. https://doi.org/10.1016/j.jsps.2014.11.010. [Google Scholar]
  56. Asghar LFA, Chandran S. Design and evaluation of matrices of Eudragit with polycarbophil and carbopol for colon-specific delivery. J Drug Targeting. 2008;16:741–757. https://doi.org/10.1080/10611860802473345. [Google Scholar]
  57. Dodi G, Pala A, Barbu E, et al. Carboxymethyl guar gum nanoparticles for drug delivery applications: Preparation and preliminary in-vitro investigations. Mater Sci Eng C. 2016;63:628–636. https://doi.org/10.1016/j.msec.2016.03.032. [Google Scholar]
  58. Ganeshkumar M, Janani M, Ponrasu T, et al. Guar gum stabilized gold nanoparticles for colon cancer treatment. Clin Oncol. 2018;3:1539. [Google Scholar]
  59. Garg S, Shukla A, Garg A. Design and characterization of Guar gum coated chitosan nanoparticles for delivery of 5-fluorouracil for effective treatment of colon cancer. J Med Pharm Allied Sci. 2015;45:28–45. [Google Scholar]
  60. Jin H, Gao S, Song D, et al. Intratumorally CpG immunotherapy with carbon nanotubes inhibits local tumor growth and liver metastasis by suppressing the epithelial-mesenchymal transition of colon cancer cells. Anti-Cancer Drugs. 2021;32:278–285. https://doi.org/10.1097/CAD.0000000000001000. [Google Scholar]
  61. González-Domínguez JM, Grasa L, Frontiñán-Rubio J, et al. Intrinsic and selective activity of functionalized carbon nanotube/nanocellulose platforms against colon cancer cells. Colloids Surf B: Biointerfaces. 2022;212:112363. https://doi.org/10.1016/j.colsurfb.2022.112363. [Google Scholar]
  62. Stang J, Haynes M, Carson P, et al. A preclinical system prototype for focused microwave thermal therapy of the breast. IEEE Trans Biomed Eng. 2012a;59:2431–2438. https://doi.org/10.1109/TBME.2012.2199492. [Google Scholar]
  63. Bharti C, Nagaich U, Pal AK, et al. Nanopartículas de sílice mesoporosa en sistemas de administración de fármacos: Una revisión. Revista Internacional de Investigación Farmacéutica. 2015;5:124. [Google Scholar]
  64. AbouAitah K, Hassan HA, Swiderska-Sroda A, et al. Targeted nano-drug delivery of colchicine against colon cancer cells by means of mesoporous silica nanoparticles. Cancers. 2020;12(1):144. https://doi.org/10.3390/cancers12010144. [Google Scholar]
  65. Chen C, Tang W, Jiang D, et al. Hyaluronic acid conjugated polydopamine functionalized mesoporous silica nanoparticles for synergistic targeted chemo-photothermal therapy. Nanoscale. 2019;11:11012–11024. https://doi.org/10.1039/c9nr01385g. [Google Scholar]
  66. Cheng W, Nie J, Xu L, et al. PH-sensitive delivery vehicle based on folic acid-conjugated polydopamine-modified mesoporous silica nanoparticles for targeted cancer therapy. ACS Appl Mater Interfaces. 2017;9:18462–18473. https://doi.org/10.1021/acsami.7b02457. [Google Scholar]
  67. Fan X, Wang T, Han M, et al. Dual CEA/CD44 targeting to colorectal cancer cells using nanobody-conjugated hyaluronic acid-modified mesoporous silica nanoparticles with pH- and redox-sensitivity. Mater Adv. 2022;3(14):4707–4717. https://doi.org/10.1039/d2ma00082b. [Google Scholar]
  68. Silva R, Ferreira H, Cavaco-Paulo A. Sonoproduction of liposomes and protein particles as templates for delivery purposes. Biomacromolecules. 2011;12:3353–3368. https://doi.org/10.1021/bm200658b. [Google Scholar]
  69. Dezfuli AAZ, Abu-Elghait M, Salem SS. Recent insights into nanotechnology in colorectal cancer. In Applied biochemistry and biotechnology (Vol. 196). Springer; 2024. p. 4457–4471. https://doi.org/10.1007/s12010-023-04696-3. [Google Scholar]
  70. Ganta S, Talekar M, Singh A, et al. Nanoemulsions in translational research – Opportunities and challenges in targeted cancer therapy. In AAPS PharmSciTech (Vol. 15). New York LLC: Springer; 2014. p. 694–708. https://doi.org/10.1208/s12249-014-0088-9. [Google Scholar]
  71. Sánchez-López E, Guerra M, Dias-Ferreira J, et al. Current applications of nanoemulsions in cancer therapeutics. Nanomater (Basel, Switzerland). 2019;9:821. https://doi.org/10.3390/nano9060821. [Google Scholar]
  72. Huang RF, Wei YJ, Inbaraj BS, et al. Inhibition of colon cancer cell growth by nanoemulsion carrying gold nanoparticles and lycopene. Int J Nanomed. 2015;10:2823–2846. https://doi.org/10.2147/IJN.S79107. [Google Scholar]
  73. Alshaman R, Alattar A, El-Sayed RM, et al. Formulation and characterization of doxycycline-loaded polymeric nanoparticles for testing antitumor/antiangiogenic action in experimental colon cancer in mice. Nanomaterials. 2022;12:857. https://doi.org/10.3390/nano12050857. [Google Scholar]

Current usage metrics show cumulative count of Article Views (full-text article views including HTML views, PDF and ePub downloads, according to the available data) and Abstracts Views on Vision4Press platform.

Data correspond to usage on the plateform after 2015. The current usage metrics is available 48-96 hours after online publication and is updated daily on week days.

Initial download of the metrics may take a while.